11results about How to "Reduce clearance" patented technology

Provided herein are compounds of formula (I) wherein Ra, Rb, Rc, A and p have the meanings given in the specification, as defined in formula (I), as well as pharmaceutically acceptable salts and solvates thereof, which are useful in the treatment of diseases in which pan-immune proteasome inhibition is desired or desired, and in particular in the treatment of cancer.

The invention discloses an anti-wrinkle and skin-brightening composition containing hydrolyzed ginsenosides and ergothioneine as well as a preparation method and application of the anti-wrinkle and skin-brightening composition, and belongs to the technical field of cosmetics. The composition is prepared from the following components in parts by weight: 5 to 15 parts of ergothioneine, 25 to 40 parts of sphingomonas fermentation product extract, 15 to 30 parts of hydrolyzed ginsenosides and 30 to 40 parts of iris vetiveria root extract. Wherein the hydrolyzed ginsenosides are prepared by enzymolysis of a specific compound enzyme. The four components in the composition synergistically construct an anti-oxidation-anti-inflammation-collagen promotion-collagen degradation inhibition system, the composition has excellent anti-wrinkle, skin brightening, soothing and anti-oxidation effects, and the composition is good in safety, suitable for various skin types, capable of being prepared into essence, emulsion and other cosmetics according to the dosage of 0.01 wt%-30 wt% and wide in application prospect.

The invention belongs to the technical field of cosmetics, and particularly relates to a natural-source composition with ultraviolet absorption and ultraviolet conversion functions and application of the natural-source composition in cosmetics. The natural source composition provided by the invention comprises a honeysuckle flower extract, a butterflybush flower and leaf extract and a spirulina platensis extract, wherein the mass ratio of the honeysuckle flower extract to the butterflybush flower and leaf extract to the spirulina platensis extract is (5-30): (1-20): (0.01-10). The natural-source composition provided by the invention not only can effectively absorb UVC, UVB and UVA full-wave band ultraviolet light, but also can convert the ultraviolet light into red light beneficial to a human body, so that the effects of resisting inflammation, repairing, fading red light, resisting light damage and resisting light aging are achieved. The natural-source composition provided by the invention is applied to cosmetics and can play a role in sunscreen and synergism. Meanwhile, the composition provided by the invention is natural, green, high in safety, mild and non-irritant, and can be used for children and people with sensitive skin.

This invention relates to the use of peptides as therapeutic agents for degenerative brain diseases. Specifically, it confirms that the peptides of this invention, by targeting microglia, induce microglia in an inflammatory state to an anti-inflammatory state in a disease environment, thereby reducing neuroinflammation and enhancing phagocytic function to clear amyloid-β. Furthermore, in animal models of degenerative brain diseases, the effects of reducing amyloid-β, restoring synaptic plasticity, and improving cognitive impairments related to anxiety, learning, and memory have been confirmed. Therefore, the peptides of this invention can be effectively used as active ingredients in compositions for the prevention or treatment of degenerative brain diseases and the resulting cognitive, learning, or memory impairments.

The present application relates to a method for preparing extracellular vesicles with reduced non-specific binding / endocytosis, which is obtained by knockout and deglycosylation of extracellular vesicle-related adhesion molecules, and the extracellular vesicles with reduced non-specific binding / endocytosis have a prolonged residence time in blood, further, IL12 and antibodies are loaded on the extracellular vesicles with reduced non-specific binding / endocytosis, to achieve the effect of IL12 "multimer" mode enhancement, further, the antibodies achieve targeting, reduce the effective concentration of IL12, improve safety, and also achieve high-efficiency inhibition of tumor growth under certain safety.

The application discloses a virus-like particle carrier based on a porcine paternal expression gene 10 and application thereof in mRNA delivery, and belongs to the technical field of genetic engineering and biological medicine. The virus-like particle is formed through self-assembly after the nucleocapsid domain of the porcine paternal expression gene 10 (SsPEG10) is deleted and replaced with a lambda phage lambda N peptide segment or an MS2 phage coat protein MCP in situ. The target mRNA is specifically packaged into the VLP interior by using the high-specificity RNA-protein interaction between the lambda N peptide segment and the 12xBoxB RNA stem loop structure or the MCP and the 12xMS2 RNA stem loop structure, and VSV-G is co-expressed during the VLP assembly process, so that the VLP is endowed with the membrane fusion ability mediated by endocytosis. Finally, the recombined VLP carrier capable of efficiently packaging the target mRNA is successfully constructed, the target mRNA can be delivered into target cells, and efficient expression and translation of the target protein are realized.

This invention relates to the field of pharmaceutical preparation technology, specifically to a sulfachlorpyridazine sodium-methotrexate suspension, its preparation method, and its application. The sulfachlorpyridazine sodium-methotrexate suspension of this invention comprises the following components per 100 ml: 20-50 g of sulfachlorpyridazine sodium, 4-10 g of methotrexate, 0.1-0.25 g of suspending agent, 0.05-0.125 g of wetting agent, 0.2-0.5 g of antioxidant, 0.1-0.25 g of disodium edetate, and purified water to a final volume of 100 ml. The suspension prepared by this invention can delay the in vivo clearance of sulfachlorpyridazine sodium, prolong the synergistic effect time, and improve its bioavailability; in the treatment of coccidiosis infection in chickens and sheep, it can significantly improve weight gain, reduce intestinal lesion values, rapidly clear oocysts, and maintain a long-lasting protective effect after drug withdrawal.

This application relates to a modified chitosan coating for enhancing adhesion to fruit surfaces and resisting fungal spores, and a method for preparing the same. The modified chitosan coating comprises a chitosan-tannic acid-stearic acid copolymer, a plasticizer, and water. The copolymer is modified by grafting tannic acid and stearic acid onto a chitosan backbone. The modified chitosan coating exhibits enhanced adhesion and hydrophobicity to hydrophobic fruit surfaces, improves wettability, reduces swelling under high humidity, enhances gas barrier properties, displays significant antioxidant activity, reduces enzymatic browning and scavenges free radicals, exhibits anti-adhesion against fungi and bacteria, and possesses excellent biocompatibility. It provides a promising, safe, and sustainable solution for extending the shelf life and quality of fresh agricultural products.

The application discloses a series of glutarimide derivatives and application thereof, and specifically discloses a compound shown in formula (VI-1), a stereoisomer or a pharmaceutically acceptable salt thereof.